Get the Stockscreener App
267.83
3.39%
7.20
Penumbra Inc stock is traded at $267.83, with a volume of 15,192.
It is up +3.39% in the last 24 hours and up +0.30% over the past month.
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. It operates as one reportable segment and its business activity consists of the design, development, manufacturing and marketing of inventive medical products.
See More
Previous Close:
$260.63
Open:
$268.19
24h Volume:
15,192
Relative Volume:
0.04
Market Cap:
$10.04B
Revenue:
$1.16B
Net Income/Loss:
$34.55M
P/E Ratio:
311.43
EPS:
0.86
Net Cash Flow:
$134.18M
1W Performance:
-1.94%
1M Performance:
+0.30%
6M Performance:
+44.15%
1Y Performance:
+17.40%
1-Day Range:
$264.93
$269.92
1-Week Range:
$254.50
$272.71
52-Week Range:
$148.00
$310.00
Penumbra Inc Stock (PEN) Company Profile
Name
Penumbra Inc
Sector
Industry
Phone
(510) 995-2486
Address
ONE PENUMBRA PLACE, ALAMEDA, CA
Compare PEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PEN
Penumbra Inc
|
269.08 | 10.04B | 1.16B | 34.55M | 134.18M | 0.86 |
|
ABT
Abbott Laboratories
|
127.34 | 225.27B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
96.33 | 140.74B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
367.05 | 138.77B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
92.91 | 118.39B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
68.38 | 39.95B | 5.72B | 4.17B | 259.90M | 6.97 |
Penumbra Inc Stock (PEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-21-25 | Initiated | UBS | Buy |
| Dec-17-24 | Initiated | Oppenheimer | Outperform |
| Dec-11-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Sep-18-24 | Initiated | Stifel | Buy |
| Sep-03-24 | Initiated | Leerink Partners | Outperform |
| Jul-31-24 | Downgrade | Citigroup | Buy → Neutral |
| Jul-31-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-23-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-06-23 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| Mar-29-23 | Downgrade | Needham | Buy → Hold |
| Jan-30-23 | Initiated | Piper Sandler | Overweight |
| Nov-04-22 | Upgrade | Citigroup | Neutral → Buy |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Oct-05-22 | Downgrade | Citigroup | Buy → Neutral |
| Sep-09-22 | Upgrade | Needham | Hold → Buy |
| Jul-18-22 | Initiated | RBC Capital Mkts | Outperform |
| Apr-19-22 | Initiated | Deutsche Bank | Buy |
| Mar-08-22 | Initiated | Needham | Hold |
| Sep-16-21 | Initiated | Truist | Buy |
| Jun-04-21 | Upgrade | BTIG Research | Neutral → Buy |
| Dec-16-20 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-07-20 | Resumed | Canaccord Genuity | Buy |
| Sep-29-20 | Initiated | BTIG Research | Buy |
| Sep-08-20 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| May-30-19 | Upgrade | JP Morgan | Neutral → Overweight |
| May-21-19 | Initiated | William Blair | Outperform |
| Oct-29-18 | Resumed | BofA/Merrill | Buy |
| Oct-08-18 | Initiated | RBC Capital Mkts | Outperform |
| Feb-21-18 | Initiated | William Blair | Outperform |
| Jan-02-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-30-15 | Reiterated | Canaccord Genuity | Buy |
| Oct-13-15 | Initiated | Wells Fargo | Outperform |
View All
Penumbra Inc Stock (PEN) Latest News
Penumbra, Inc. (NYSE:PEN) Shares Acquired by Charles Schwab Investment Management Inc. - Defense World
Penumbra, Inc. (NYSE:PEN) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Penumbra Off And Running On Renewed Enthusiasm For Mechanical Thrombectomy - Seeking Alpha
Adam Elsesser Sells 61,600 Shares of Penumbra, Inc. (NYSE:PEN) Stock - Defense World
Penumbra CEO Adam Elsesser sells $17.47 million in stock By Investing.com - Investing.com Canada
Penumbra CEO Adam Elsesser sells $17.47 million in stock - Investing.com
Penumbra director O’Rourke sells $14,274 in stock By Investing.com - Investing.com South Africa
Penumbra director Arani sells $3.45 million in stock By Investing.com - Investing.com South Africa
Penumbra’s Growth Potential Balanced by Market Uncertainties: A Hold Recommendation - TipRanks
Penumbra, Inc. to Host Earnings Call - ACCESS Newswire
Insider Sell: Arani Bose Sells 12,000 Shares of Penumbra Inc (PE - GuruFocus.com
Insider Sell: Bridget O'Rourke Sells Shares of Penumbra Inc (PEN) - GuruFocus.com
Penumbra director O’Rourke sells $14,274 in stock - Investing.com India
Penumbra EVP Johanna Roberts sells shares worth $172,458 - Investing.com India
Penumbra EVP Johanna Roberts sells shares worth $172,458 By Investing.com - Investing.com South Africa
Penumbra’s chief accounting officer sells shares worth over $2.2 million - Investing.com
Penumbra CFO Maggie Yuen sells $571,994 in stock - Investing.com
Penumbra director Arani sells $3.45 million in stock - Investing.com
Penumbra Announces Board Transition with Kassing’s Retirement - TipRanks
Aspiration-first approaches gather further traction thanks to ‘game-changing’ thrombectomy technologies - NeuroNews International
Penumbra Inc.: Will Its Market Penetration & Access Initiatives Help Capture The Thrombectomy Market? - Smartkarma
Los Angeles Capital Management LLC Raises Position in Penumbra, Inc. (NYSE:PEN) - MarketBeat
Penumbra Investor Alert: Shareholder Lawsuit Filed - ACCESS Newswire
Growing Thrombectomy Business Supports PEN Stock, Macro Issues Ail - MSN
Acute Pulmonary Embolism Treatment Market Size in the 7MM - openPR
Q1 Earnings Estimate for Penumbra Issued By Leerink Partnrs - MarketBeat
Penumbra Inc. Faces Financial Peril Amid Rising Customer Payment Defaults - TipRanks
Penumbra (NYSE:PEN) Stock Rating Upgraded by StockNews.com - MarketBeat
Robert W. Baird Boosts Penumbra (NYSE:PEN) Price Target to $328.00 - MarketBeat
Penumbra (PEN) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Penumbra (NYSE:PEN) Releases Earnings Results, Beats Expectations By $0.09 EPS - MarketBeat
Penumbra (PEN) Upgraded to Buy: Here's Why - MSN
Piper Sandler Reiterates Overweight Rating for Penumbra (NYSE:PEN) - MarketBeat
Penumbra, Inc. Just Missed EarningsBut Analysts Have Updated Their Models - Yahoo Finance
Penumbra targets 13%-14% revenue growth for 2025 with focus on thrombectomy market expansion - MSN
Penumbra price target raised to $320 from $305 at UBS - TipRanks
Penumbra Announces Don Kassing Will Retire From Board Of Directors -February 21, 2025 at 05:50 pm EST - Marketscreener.com
Penumbra, Inc. Announces Don Kassing will Retire from Board of Directors - PR Newswire
Neuro-interventional Devices Market Growth in Future Scope - openPR
Why Penumbra (PEN) Stock Is Trading Up Today - MSN
Penumbra Inc. Earnings Call Reveals Strong U.S. Growth - TipRanks
Here's What Key Metrics Tell Us About Penumbra (PEN) Q4 Earnings - MSN
Stroke Device Maker Penumbra Stock Surges On Earnings Beat, Analysts Boost Price Forecasts After Upbeat 2025 Outlook - Benzinga India
Penumbra Inc Stock (PEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.57%
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):